

Drug Name	Indication Neurotransmitter(s) Affected Target Symptoms	Half-life (T1/2), Metabolism (CYP 450 enzyme)	Notable Side Effects (link to NT or affected brain circuit)	Initial Dose Considerations Specific life considerations pregnancy,
Buprenorphine (Subutex)	<p>Indication:</p> <ul style="list-style-type: none"> Maintenance treatment of opioid dependence Maintenance treatment of opioid dependence in patients who have achieved and sustained prolonged clinical stability on low-to-moderate doses of a transmucosal buprenorphine-containing product Moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-containing product, followed by dose adjustment for a minimum of 7 days <p>Neurotransmitters:</p> <ul style="list-style-type: none"> Mu opioid receptor partial agonist 	<p>Half-life: 24-42 hours</p> <p>CYP450: CYP3A4</p>	<ul style="list-style-type: none"> Headache, constipation, nausea Oral hypoesthesia, glossodynia Orthostatic hypotension Implant specific: insertion site pain, pruritis, erythema Respiratory depression Hepatotoxicity 	<p>Initial dosing:</p> <p>Day 1: 8 mg</p> <p>Day 2: 12 mg</p> <p>Days 3-7: 16 mg</p> <p>increments maximum</p> <p>Considerations:</p> <ul style="list-style-type: none"> Use in patients with the cardiac implantable cardioverter-defibrillator (ICD) or pacemaker (PM) should be avoided. Major depressive disorder, premenstrual dysphoric disorder, or premenstrual syndrome. Neuroleptic malignant syndrome (NMS) with or without rhabdomyolysis may occur. Drug interactions: buprenorphine may reduce the effectiveness of DC and fecal softeners. Safety: effectiveness may be reduced for additional